PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.92%
Cash & equivalents declining -42.92% while TRAW's grows 2.91%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-42.83%
Cash + STI yoy ≥ 1.5x TRAW's -24.00%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.38%
≥ 1.5x TRAW's -23.89%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-9.44%
0.5-0.75x TRAW's -17.97%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.57%
Below half of TRAW's -33.44%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-39.92%
≥ 1.5x TRAW's -23.99%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
31.92%
Less than half of TRAW's -25.22%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.79%
Less than half of TRAW's -58.67%. David Dodd sees fewer expansions in other current obligations.
-7.19%
Less than half of TRAW's -21.34%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.19%
50-75% of TRAW's -10.88%. Bruce Berkowitz notes a lower yoy liability increase.
1.19%
Higher Common Stock (Book Value) Growth compared to TRAW's zero value, indicating worse performance.
-6.33%
1.25-1.5x TRAW's -4.76%. Bruce Berkowitz notes stronger reinvestment strategy.
-55.74%
Similar yoy to TRAW's -62.50%. Walter Schloss sees parallel comprehensive income changes.
No Data
No Data available this quarter, please select a different quarter.
-181.05%
≥ 1.5x TRAW's -35.50%. David Dodd sees stronger capital base growth than competitor.
-39.92%
≥ 1.5x TRAW's -23.99%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.34%
Less than half of TRAW's -2.91%. David Dodd sees better deleveraging or stronger cash buildup than competitor.